New Speciality Pharma Customer for new Indication

RNS Number : 0763U

Physiomics PLC

04 April 2016

 

Physiomics plc

("Physiomics") or ("the Company")

New Speciality Pharma Customer for new Indication

Further to the announcement of 22 December 2015, Physiomics is pleased to announce that it has signed a further contract with a speciality pharmaceutical company.  This extension to the work will be completed by the end of 2016.

The project will be performed on a fee-for-service basis, at Physiomics' standard rate.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to have extended the PK/PD work we are performing for this new key customer.  We hope to gain yet more business with this customer and similar clients in the future."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

MSCSSSFFLFMSEFL